OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Dermatology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Integrating artificial intelligence into skin cancer pathways: the opportunities and obstacles	302
Greater understanding about differences in the long-term course of eczema and their risk factors in children	222
Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights	178
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin	102
561 - Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial	97
Higher proportion of cellulitis in severe lymphoedema	89
一项在一家大型教学医院进行的 5 年皮肤附属器肿瘤研究, 对关联基因诊断提供了启示	83
对化疗所致脱发的更深入了解	80
空气污染会导致皮肤颜色变深	76
P100: Efficacy of current treatments under study in patients with alopecia areata	75
Recognizing psoriasis in children and adolescents: the DIPSOC study	75
BH13: Scarring alopecia affecting a congenital melanocytic naevus in a patient with frontal fibrosing alopecia	74
CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease	71
P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future	71
P57: New order: redesigning referral pathways to improve access for patients from dermatology outpatient waiting lists	70
开展健康宣传活动，禁售日光浴床，以减少皮肤癌: 合理利用医疗预算	69
Issue Information	64
H10: A Sweet diagnosis to make: the history of Robert Douglas Sweet and acute febrile neutrophilic dermatosis	64
P52: Opportunities for implementing a patient‐initiated follow‐up pathway in patients with psoriasis completing narrowband ultraviolet B phototherapy	64
BH09: Frontal fibrosing alopecia in men: is it any different?	64
News and Notices	61
Possible new oral treatment for hidradenitis suppurativa	60
DP27: Maculopapular cutaneous mastocytosis mimicking seborrhoeic folliculitis	58
P53: Office 365: Microsoft Lists as a tool for a secure online second‐line/systemic drug database	57
皮肤红斑狼疮治疗指南	56

DP12: An 11‐year mystery	55
Editor's Choice – John Ingram – Sep 2023	54
P91: Cutaneous adverse events of immune check point inhibitors nivolumab, pembrolizumab and atezolizumab: a multicentric study	54
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?	53
Correction	52
银屑病皮肤细胞中的小分子 RNA 促进炎症发生	52
Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review	51
O22 Unravelling the pathophysiology of KLICK syndrome to identify therapeutically targetable pathways	51
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis	50
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing	48
Development of a shared decision-making tool in vitiligo: an international study	48
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with ‘skyline’ basal cell layer (PENS)	47
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study	47
Atypical melanocytes of an atypical Spitz tumour observed with optical super-high magnification dermoscopy	46
Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma	45
Seeking new topical therapies in psoriasis	43
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme	42
How to score the impact of treatment on cutaneous neurofibromas in clinical trials	42